Doxorubicin stimulates skeletal muscle myotube atrophy via mitochondrial ROS, a process that can be mitigated by the mitochondrial-targeted antioxidant SS31.
No takes yet. Share an insight, caveat, or question.
Does not support SS31 use with doxorubicin; hypothesis-generating for mitochondrial antioxidants in chemotherapy myopathy.
Gilliam et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: